Characterization of metabolites and cytochrome P450 isoforms involved in the microsomal metabolism of aconitine

被引:123
作者
Wang, Yuguang
Wang, Shengqi
Liu, Yongxue
Yan, Liangping
Dou, Guifang
Gao, Yue [1 ]
机构
[1] Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing 100850, Peoples R China
[2] Natl Ctr Biomed Anal, Beijing 100850, Peoples R China
[3] Beijing Inst Transfus Med, Dept New Drug Preclin Evaluat, Beijing 100850, Peoples R China
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2006年 / 844卷 / 02期
基金
中国国家自然科学基金;
关键词
aconitine; cytochrome P450; metabolites; metabolism; microsome;
D O I
10.1016/j.jchromb.2006.07.059
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Aconitine, a major Aconitum alkaloid, is well known for its high toxicity that induces severe arrhythmias leading to death. The current study investigated the metabolism of aconitine and the effects of selective cytochrome P450 (CYP) inhibitors on the metabolism of aconitine in rat liver microsomes. The metabolites were separated and assayed by liquid chromatography-ion trap mass spectrometry (LC/MSn) and further identified by comparison of their mass spectra and chromatographic behaviors with reference substances. Various selective inhibitors of CYP were used to identify the isoforms of CYP, that involved in the metabolism of aconitine. A total of at least six metabolites were found and characterized in rat liver microsomal incubations. Result showed that the inhibitor of CYP 3A had an inhibitory effect on aconitine metabolism in a concentration-dependant manner, the inhibitor of CYP1A1/2 had a modest inhibitory effect, whereas inhibitors of CYP2B1/2, 2D and 2E1 had no obvious inhibitory effects on aconitine metabolism. Aconitine might be metabolized by CYP 3A and CYP1A1/2 isoforms in rat liver microsome. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:292 / 300
页数:9
相关论文
共 26 条
[1]
The effects of Aconitum alkaloids on the central nervous system [J].
Ameri, A .
PROGRESS IN NEUROBIOLOGY, 1998, 56 (02) :211-235
[2]
Determination of aconitine in body fluids by LC-MS-MS [J].
Beike, J ;
Frommherz, L ;
Wood, M ;
Brinkmann, B ;
Köhler, H .
INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2004, 118 (05) :289-293
[4]
Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats [J].
Chung, HJ ;
Choi, YH ;
Kim, SH ;
Lee, MG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (04) :449-457
[5]
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[6]
REGULATION OF CYTOCHROME-P450 GENES - MOLECULAR MECHANISMS [J].
GONZALEZ, FJ ;
LIU, SY ;
YANO, M .
PHARMACOGENETICS, 1993, 3 (01) :51-57
[7]
GUENGERICH FP, 1994, TOXICOL LETT, V70, P133
[8]
HASEGAWA T, 1994, DRUG METAB DISPOS, V22, P916
[9]
Ritonavir - Clinical pharmacokinetics and interactions with other anti-HIV agents [J].
Hsu, A ;
Granneman, GR ;
Bertz, RJ .
CLINICAL PHARMACOKINETICS, 1998, 35 (04) :275-291
[10]
The detection of cytochrome P450 2E1 and its catalytic activity in rat testis [J].
Jiang, YC ;
Kuo, CL ;
Pernecky, SJ ;
Piper, WN .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 246 (03) :578-583